Overview
ATNM market data
Price History
ATNM price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.09 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.31 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -5,701.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.74 – $1.81 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $25.8M · P/B 5.42 · P/S 286.85.
Company News
Actinium Pharmaceuticals Advances Actimab-A Program With New Patents, Expanded Manufacturing Capacity And Clinical Milestones Into 2027Benzinga · Aug 14, 2026, 9:05 PM
Actinium Pharmaceuticals Receives NYSE American Compliance Plan Acceptance, Granted Until Nov. 27, 2027 To Regain Listing ComplianceBenzinga · Aug 14, 2026, 9:04 PM
8-K filing — Actinium Pharmaceuticals, Inc. (ATNM)SEC EDGAR · Aug 14, 2026, 9:00 PM
Actinium Pharmaceuticals Q2 EPS $0.89 Beats $(0.21) Estimate, Sales $35.000MBenzinga · Aug 12, 2026, 10:47 AM
Actinium Pharmaceuticals On May 31, 2026 Presented New Radiochemistry Data At The Society Of Nuclear Medicine And Molecular Imaging (Snmmi) 2026 Annual Meeting Taking Place In Los Angeles, CaliforniaBenzinga · Jun 1, 2026, 11:08 AM
Actinium Pharmaceuticals Obtains Two Patent Allowances Spanning Its Actimab-A And Iomab-ACT ProgramsBenzinga · May 29, 2026, 9:35 PM
Actinium Pharmaceuticals To Reveal ATNM-400 Program Update At SNMMI 2026 Conference on May 31-June 2; Co. Receives NYSE Noncompliance NoticeBenzinga · May 29, 2026, 9:35 PM